INCREASED FIBRINOLYTIC POTENTIAL INDUCED BY GLICLAZIDE IN TYPE-I AND TYPE-II DIABETIC-PATIENTS

被引:3
作者
GRAM, J
JESPERSEN, J
机构
[1] RIBE CTY HOSP,DEPT CLIN CHEM,COAGULAT & FIBRINOLYSIS SECT,ESBJERG,DENMARK
[2] S JUTLAND UNIV CTR,THROMBOSIS RES SECT,ESBJERG,DENMARK
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 1992年 / 41卷 / 05期
关键词
D O I
10.1016/0026-0495(92)90090-W
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite the fact that the relationship between impaired diabetic control and the development of vascular complications now seems less controversial than before, we are still in a situation where interventions or strategies aimed at decreasing the complications of late diabetes have high priorities. It is believed that accelerated vascular disease in the diabetic population is caused by repeated intimal injury of the arteries, and there is also evidence that the accelerated vascular disease states cannot be attributed only to the hyperglycemic state. One factor of importance for delayed tissue repair and arteriosclerotic disease in diabetic patients might be a disordered endothelial cell-dependent fibrinolytic system. Here, we review the evidence of the relationship between increased fibrin deposition and defective fibrinolysis in diabetic patients, and, furthermore, we discuss the possible beneficial effects of an enhancement of endogenous endothelial cell-related fibrinolysis by sulphonylurea drugs. © 1992.
引用
收藏
页码:25 / 29
页数:5
相关论文
共 43 条
[2]  
ASTRUP T, 1956, LANCET, V2, P565
[3]   TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS [J].
AUWERX, J ;
BOUILLON, R ;
COLLEN, D ;
GEBOERS, J .
ARTERIOSCLEROSIS, 1988, 8 (01) :68-72
[5]  
CHAKRABARTI R, 1972, LANCET, V2, P556
[6]  
CHAN TK, 1982, SEM HOP PARIS, V58, P1197
[7]  
CHRISTE M, 1984, THROMB HAEMOSTASIS, V52, P138
[8]  
DEWOOD MA, 1984, NEW ENGL J MED, V311, P1413
[9]  
DUHAULT J, 1980, ROY SOC MED INT CONG, V20, P9
[10]  
FEARNLEY GR, 1967, LANCET, V2, P1008